Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H18ClFN2O3 |
Molecular Weight | 376.809 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCN1C2=CC=C(Cl)C=C2C3(OCCN3CC1=O)C4=CC=CC=C4F
InChI
InChIKey=WMFSSTNVXWNLKI-UHFFFAOYSA-N
InChI=1S/C19H18ClFN2O3/c20-13-5-6-17-15(11-13)19(14-3-1-2-4-16(14)21)22(8-10-26-19)12-18(25)23(17)7-9-24/h1-6,11,24H,7-10,12H2
Molecular Formula | C19H18ClFN2O3 |
Molecular Weight | 376.809 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://med.sawai.co.jp/file/pr22_1083.pdf
Sources: http://med.sawai.co.jp/file/pr22_1083.pdf
Flutazolam is a benzodiazepine derivative developed in Japan by Mitsui. The drug is marketed under the name Coreminal and used for the treatment of gastrointestinal disorders. The mechanism of flutazolam action is due to activation of GABA-A receptors as it has affinity to the benzodiazepine binding sites.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2109243 Sources: http://med.sawai.co.jp/file/pr22_1083.pdf |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | COREMINAL Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Psychopharmacological effects of flutazolam (MS-4101) (author's transl)]. | 1978 Nov |
|
The behavior of 1,4-benzodiazepine drugs in acidic media. V. Kinetics of hydrolysis of flutazolam and haloxazolam in aqueous solution. | 1986 Jan |
|
Simultaneous determination of twelve benzodiazepines in human serum using a new reversed-phase chromatographic column on a 2-microns porous microspherical silica gel. | 1996 Jun 28 |
|
Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. | 2017 Apr |
Sample Use Guides
In Vivo Use Guide
Sources: http://med.sawai.co.jp/file/pr22_1083.pdf
The usual adult dose is 12 mg administered 3 times/day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:47:31 GMT 2023
by
admin
on
Fri Dec 15 15:47:31 GMT 2023
|
Record UNII |
5G2K7O5D8S
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1012
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1697836
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
m1171
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB07757MIG
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
5G2K7O5D8S
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
C65737
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
3682
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
1224
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
100000080955
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
3398
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
Flutazolam
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
C013367
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
DTXSID6023072
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY | |||
|
27060-91-9
Created by
admin on Fri Dec 15 15:47:31 GMT 2023 , Edited by admin on Fri Dec 15 15:47:31 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |